Progastrin-releasing peptide (ProGRP)
Screening and diagnosis. ProGRP is a reliable marker for SCLC, with good specificity and
sensitivity (73-76), although in view of the incidence of SCLC in the general population these
are not high enough to allow its use in screening. However it is rarely elevated in other
malignancies, and if so, generally only mildly.
Renal disease may cause elevations up to 300 ng/L, but raised concentrations are not seen in other benign diseases. ProGRP
concentrations >200 ng/L are highly suspicious for lung cancer, and concentrations >300
ng/L for SCLC if renal function is not impaired (73,75-77).
ProGRP has shown to be helpful in differential diagnosis, particularly in distinguishing
SCLC from other lung cancers. When used as a single marker, it is superior to NSE, while
combining both markers provides additional information. ProGRP is released in measurable
amounts in early stage SCLC and does not correlate with tumor extent (14,16,18,73,75-81).
Prognosis and monitoring. Only one report supports the use of ProGRP in prognosis. (82).
However, several studies suggest it may be useful in monitoring SCLC
(16,32,73,78,79,82,83) or detecting recurrent disease after primary therapy (16,82-84).
Analytical concerns. Because of the instability of GRP in serum, the more stable recombinant
ProGRP [31-98] was developed as serum parameter. ProGRP values may also be
significantly elevated due to renal failure.
http://www.researchgate.net/publication/242354126_National_Academy_of_Clinical_Biochemistry_Guidelines_for_the_Use_of_Tumor_Markers_in_Lung_Cancer/links/00463529d77f26584b000000
Screening and diagnosis. ProGRP is a reliable marker for SCLC, with good specificity and
sensitivity (73-76), although in view of the incidence of SCLC in the general population these
are not high enough to allow its use in screening. However it is rarely elevated in other
malignancies, and if so, generally only mildly.
Renal disease may cause elevations up to 300 ng/L, but raised concentrations are not seen in other benign diseases. ProGRP
concentrations >200 ng/L are highly suspicious for lung cancer, and concentrations >300
ng/L for SCLC if renal function is not impaired (73,75-77).
ProGRP has shown to be helpful in differential diagnosis, particularly in distinguishing
SCLC from other lung cancers. When used as a single marker, it is superior to NSE, while
combining both markers provides additional information. ProGRP is released in measurable
amounts in early stage SCLC and does not correlate with tumor extent (14,16,18,73,75-81).
Prognosis and monitoring. Only one report supports the use of ProGRP in prognosis. (82).
However, several studies suggest it may be useful in monitoring SCLC
(16,32,73,78,79,82,83) or detecting recurrent disease after primary therapy (16,82-84).
Analytical concerns. Because of the instability of GRP in serum, the more stable recombinant
ProGRP [31-98] was developed as serum parameter. ProGRP values may also be
significantly elevated due to renal failure.
http://www.researchgate.net/publication/242354126_National_Academy_of_Clinical_Biochemistry_Guidelines_for_the_Use_of_Tumor_Markers_in_Lung_Cancer/links/00463529d77f26584b000000
選擇“Disable on www.wenxuecity.com”
選擇“don't run on pages on this domain”
